Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred R Hirsch

Showing results (51-60 of 405) with videos related to

Pageof 41
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
The biology of epidermal growth factor receptor in lung cancerGiorgio V Scagliotti, Giovanni Selvaggi, Silvia Novello, et al.
Cancer Research|May 20, 2016
Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-LetterKenichi Suda, Christopher J Rivard, Tetsuya Mitsudomi, et al.
Immunotherapy|July 20, 2010
MAGE A3 antigen-specific cancer immunotherapeuticNir Peled, Ana B Oton, Fred R Hirsch, et al.
Lancet (London, England)|September 7, 2016
New and emerging targeted treatments in advanced non-small-cell lung cancerFred R Hirsch, Kenichi Suda, Jacinta Wiens, et al.
Expert Review of Anticancer Therapy|July 14, 2017
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanismsKenichi Suda, Christopher J Rivard, Tetsuya Mitsudomi, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2015
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trialJohn Hornberger, Fred R Hirsch, Qianyi Li, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancerNir Peled, Koichi Yoshida, Murry W Wynes, et al.
The Lancet. Oncology|June 24, 2010
Molecularly targeted therapy: when to stop and when to continue?Fred R Hirsch, Tony S Mok, Virginia Borges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?Rafal Dziadziuszko, Fred R Hirsch, Marileila Varella-Garcia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Targeting anemia in patients with lung cancerJeffrey Crawford, Paris A Kosmidis, Fred R Hirsch, et al.
Pageof 41

Showing results (51-60 of 405) with videos related to

Sort By:
Pageof 41
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
The biology of epidermal growth factor receptor in lung cancerGiorgio V Scagliotti, Giovanni Selvaggi, Silvia Novello, et al.
Cancer Research|May 20, 2016
Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-LetterKenichi Suda, Christopher J Rivard, Tetsuya Mitsudomi, et al.
Immunotherapy|July 20, 2010
MAGE A3 antigen-specific cancer immunotherapeuticNir Peled, Ana B Oton, Fred R Hirsch, et al.
Lancet (London, England)|September 7, 2016
New and emerging targeted treatments in advanced non-small-cell lung cancerFred R Hirsch, Kenichi Suda, Jacinta Wiens, et al.
Expert Review of Anticancer Therapy|July 14, 2017
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanismsKenichi Suda, Christopher J Rivard, Tetsuya Mitsudomi, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2015
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trialJohn Hornberger, Fred R Hirsch, Qianyi Li, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancerNir Peled, Koichi Yoshida, Murry W Wynes, et al.
The Lancet. Oncology|June 24, 2010
Molecularly targeted therapy: when to stop and when to continue?Fred R Hirsch, Tony S Mok, Virginia Borges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?Rafal Dziadziuszko, Fred R Hirsch, Marileila Varella-Garcia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Targeting anemia in patients with lung cancerJeffrey Crawford, Paris A Kosmidis, Fred R Hirsch, et al.
Pageof 41